MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Strona główna・Stock List・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Closed

SectorHealthcare

339.06 1.82

Buy Sell

Overview

Share price change

24h

Current

Min

329.96

Max

343.01

Key metrics
By Trading Economics
Income	-65M 186M
Sales	-152M 1.1B
P/E Sector Avg	141.777 66.418
EPS	1.25
Profit margin	16.993
Employees	2,500
EBITDA	-152M 145M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+35.88% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.5B 44B
Previous open	337.24
Previous close	339.06

Technical Score

By Trading Central

Confidence

Bullish Evidence

256.565 / 269.81 Support & Resistance

Alnylam Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 kwi 2026, 23:36 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 kwi 2026, 23:24 UTC

Hot Stocks

Stocks to Watch: Gloo, Broadcom, GitLab

14 kwi 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 kwi 2026, 21:32 UTC

Major Market Movers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 kwi 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 kwi 2026, 22:54 UTC

Earnings

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 kwi 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 kwi 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 kwi 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 kwi 2026, 22:13 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

14 kwi 2026, 20:33 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 20:32 UTC

Hot Stocks

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 kwi 2026, 19:59 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 19:38 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 kwi 2026, 19:21 UTC

Market Talk

Major News Events

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 kwi 2026, 19:09 UTC

Acquisitions, Mergers, Takeovers

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 kwi 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 kwi 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Comparison

Price change

Alnylam Pharmaceuticals Inc Forecast

Price Target

By TipRanks

35.88% upside

12 Months Forecast

Average 452.47 USD 35.88%

High 549 USD

Low 330 USD

Based on 20 Wall Street analysts offering 12 month price targets forAlnylam Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Alnylam Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

256.565 / 269.81Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.